Exclusive: Is Concordia International Corp’s Fuel Running Low? The Stock Reaches 52-Week Low Today

Exclusive: Is Concordia International Corp's Fuel Running Low? The Stock Reaches 52 Week Low Today

The stock of Concordia International Corp (NASDAQ:CXRX) hit a new 52-week low and has $3.59 target or 13.00% below today’s $4.13 share price. The 8 months bearish chart indicates high risk for the $219.88 million company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $3.59 price target is reached, the company will be worth $28.58M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 521,119 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 86.79% since March 10, 2016 and is downtrending. It has underperformed by 94.31% the S&P500.

Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 EPS, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $71.87M for 0.76 P/E if the $1.35 EPS becomes a reality. After $1.21 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $105 is the highest target while $13 is the lowest. The $57.50 average target is 1292.25% above today’s ($4.13) stock price. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, September 29 by Scotia Capital. The company was initiated on Monday, June 6 by Goldman Sachs. The rating was downgraded by GMP Securities to “Hold” on Monday, August 15. The rating was upgraded by Mackie on Monday, October 19 to “Speculative Buy”. Scotia Capital maintained the shares of CXRX in a report on Friday, October 16 with “Sector Outperform” rating. The stock of Concordia International Corp (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. The stock has “Neutral” rating given by Goldman Sachs on Monday, August 15. The stock of Concordia International Corp (NASDAQ:CXRX) has “Hold” rating given on Thursday, August 4 by TD Securities. The stock has “Sector Perform” rating given by IBC on Monday, November 30. S&P Research maintained Concordia International Corp (NASDAQ:CXRX) on Friday, October 16 with “Buy” rating.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp takeover unlikely – Goldman” on September 27, 2016, also Business.Financialpost.com with their article: “Concordia International Corp stock crashes on proposed U.K. legislation over …” published on September 16, 2016, Fool.ca published: “Concordia International Corp.: A Safe Buy?” on October 10, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Moodys.com and their article: “Moody’s assigns B1 to Concordia’s new secured notes; outlook to negative” published on October 06, 2016 as well as Globenewswire.com‘s news article titled: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” with publication date: September 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment